AT13387 |
synthetic, orally bioavailable and small-molecule Hsp90 inhibitor |
Sample solution is provided at 25 µL, 10mM.
Quality Control & MSDS
- View current batch:
-
Purity = 98.00%
- COA (Certificate Of Analysis)
- MSDS (Material Safety Data Sheet)
Chemical structure
| Description | AT13387 is a synthetic, orally bioavailable and small-molecule inhibitor of heat shock protein 90 (Hsp90) with IC50 value of 18 nM in A375 cells. | |||||
| Targets | Hsp90 | |||||
| IC50 | 18 nM (in A375 cells) | |||||
AT13387 Dilution Calculator
AT13387 Molarity Calculator
| Cas No. | 912999-49-6 | SDF | Download SDF |
| Chemical Name | (2,4-dihydroxy-5-propan-2-ylphenyl)-[5-[(4-methylpiperazin-1-yl)methyl]-1,3-dihydroisoindol-2-yl]methanone | ||
| Canonical SMILES | CC(C)C1=C(C=C(C(=C1)C(=O)N2CC3=C(C2)C=C(C=C3)CN4CCN(CC4)C)O)O | ||
| Formula | C24H31N3O3 | M.Wt | 409.5 |
| Solubility | Soluble in DMSO | Storage | Store at -20°C |
| Shipping Condition: | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
||
AT13387, discovered by a high-throughput x-ray craystallography fragment-based platform, is a non-geldanamycin heat shock proterin 90 (HPS90), a molecule chaperone regulating signal transduction pathways for cell growth and survival, inhibitor reportedly resulting in client protein degradation, suppression of signaling, and inducing cell cycle arrest and apoptosis. Since structurally unrelated to geldanamycin, it has high affinity for binding HSP90 (Kd = 0.5nM) and exhibited an in vitro cytotoxicity showing a median EC50 value of 41 nM. A long tumor-specific retention was observed in AT13387 during xenograft studies, which indicated the possibility of less frequent dosing. However, preliminary results showed that the antitumor activity of AT13387 against solid tumor and leukemia models is similar to alvespimycin.
Reference
Min H. Kang, C. Patrick Reynolds, Peter J. Houghton, Denise Alexander, Christopher L. Morton, E. Anders Kolb, Richard Gorlick, Stephen T. Keir, Hernan Carol, Richard Lock, John M. Maris, Amy Wozniak, and Malcolm A. Smith. Initial Testing (Stage 1) of AT13387, an HSP90 Inhibitor, by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer. 2012; 59(1): 185-188
